Dr. Hamid on Immune Therapy in Melanoma

Omid Hamid, MD
Published: Tuesday, Oct 08, 2013

Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses using immune therapy to treat patients with melanoma.

Immune therapy has the ability to give significant and durable response, Hamid says, and there are some indications of deep responses with combinatorial immunotherapeutics, such as anti-PD-1 and anti-CTLA4 combinations.

As this is a rapidly changing field, Hamid says, there are no clear guidelines for patients as a group. Each patient must be assessed individually based on pace disease growth, areas of disease metastasis and toxicity.
 
Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses using immune therapy to treat patients with melanoma.

Immune therapy has the ability to give significant and durable response, Hamid says, and there are some indications of deep responses with combinatorial immunotherapeutics, such as anti-PD-1 and anti-CTLA4 combinations.

As this is a rapidly changing field, Hamid says, there are no clear guidelines for patients as a group. Each patient must be assessed individually based on pace disease growth, areas of disease metastasis and toxicity.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x